How do you interpret the DESTINY-Breast11 data evaluating Enhertu followed by paclitaxel, trastuzumab, and pertuzumab in the neoadjuvant setting? What does this tell us about the potential of ADC-based regimens to move earlier in the treatment paradigm?

DESTINY-Breast05 compared Enhertu directly with trastuzumab emtansine (T-DM1) in patients with residual invasive disease after neoadjuvant therapy. What stands out to you in terms of efficacy and safety from this head-to-head analysis?

Considering the improved outcomes seen in high-risk HER2-positive patients, how might these results influence clinical decision-making for post-neoadjuvant therapy, especially in those with incomplete pathological response?

How does Enhertu’s mechanism as a topoisomerase I inhibitor–based ADC contribute to its superior efficacy compared with earlier HER2-targeted therapies?

Both DESTINY-Breast11 and DESTINY-Breast05 were presented in the Presidential Symposium at ESMO 2025. How significant is it for a single drug to feature prominently in multiple pivotal studies at this level, and what does that suggest about the strength of the data?

What safety considerations remain with Enhertu, particularly regarding interstitial lung disease, and how are clinicians approaching monitoring and management in real-world settings?

Given the broad HER2 expression spectrum across tumor types, do you see Enhertu expanding further beyond breast cancer, and what have these latest data shown regarding potential biomarker-driven selection?

As Enhertu continues to demonstrate benefit across early and metastatic settings, how do you foresee treatment sequencing evolving—will chemotherapy-based combinations remain central, or could ADCs like Enhertu become the new foundation of HER2-directed care?